drugset / Trial / NCT00409097

Effect of Rosiglitazone on ADMA in Critical Illness

NCT00409097

Phase 3 Unknown 30 enrolled Amsterdam UMC, location VUmc
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Rosiglitazone,decreases the ADMA concentration and thereby increases the arginine/ADMA ratio of critically ill patients.

Timeline

Start
2006-04
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule